Drug Permeability

Drug Permeability describes the capacity of pharmaceutical compounds to traverse biological membranes, fundamentally determining absorption, distribution, and cellular access required for therapeutic activity. This critical property depends on molecular characteristics including size, lipophilicity, hydrogen bonding capacity, charge state, and conformational flexibility, with passive diffusion across lipid bilayers representing the primary mechanism for most small molecule drugs. Membrane transporters can enhance or restrict permeability through active or facilitated transport, while specialised barriers like the blood-brain barrier impose additional permeability constraints.

The pharmaceutical industry extensively evaluates permeability during drug discovery and development as a key determinant of oral bioavailability and tissue distribution. In vitro permeability assays using Caco-2 cell monolayers modelling intestinal epithelium, MDCK cells, or artificial membrane systems provide screening tools predicting in vivo absorption. The Biopharmaceutics Classification System categorises drugs based on solubility and permeability, informing formulation strategies and regulatory pathways for bioequivalence. Efflux transporters like P-glycoprotein can limit permeability by actively exporting drugs from cells, potentially restricting brain penetration or reducing oral bioavailability. Development strategies addressing permeability limitations include chemical modifications improving membrane crossing, formulation approaches using penetration enhancers, and delivery systems facilitating transport. As oral delivery of biologics emerges through innovative technologies, understanding and optimising permeability remains central to achieving therapeutic drug concentrations at action sites.